Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease

被引：3

作者：

Nouso, Kazuhiro ^{[1
,2
]}

Kawanaka, Miwa ^{[3
]}

Fujii, Hideki ^{[4
]}

Kariyama, Kazuya ^{[1
,2
]}

Toyoda, Hidenori ^{[5
]}

Iwaki, Michihiro ^{[6
]}

Hayashi, Hideki ^{[7
]}

Oeda, Satoshi ^{[8
,9
]}

Hyogo, Hideyuki ^{[10
]}

Morishita, Asahiro ^{[11
]}

Munekage, Kensuke ^{[12
,13
]}

Kawata, Kazuhito ^{[14
]}

Tsutsumi, Tsubasa ^{[15
]}

Sawada, Koji ^{[16
]}

Maeshiro, Tatsuji ^{[17
]}

Tobita, Hiroshi ^{[18
]}

Yoshida, Yuichi ^{[19
]}

Naito, Masafumi ^{[19
]}

Araki, Asuka ^{[20
]}

Arakaki, Shingo ^{[21
]}

Kawaguchi, Takumi ^{[15
]}

Noritake, Hidenao ^{[14
]}

Ono, Masafumi ^{[22
]}

Masaki, Tsutomu ^{[13
]}

Yasuda, Satoshi ^{[5
]}

Tomita, Eiichi ^{[7
]}

Yoneda, Masato ^{[6
]}

Tokushige, Akihiro ^{[23
]}

Kamada, Yoshihiro ^{[24
]}

Takahashi, Hirokazu ^{[25
]}

Ueda, Shinichiro ^{[25
]}

Aishima, Shinichi ^{[26
]}

Sumida, Yoshio ^{[27
]}

Nakajima, Atsushi ^{[7
]}

Kumada, Takashi ^{[5
,28
]}

Okanoue, Takeshi ^{[29
]}

机构：

[1] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[2] Okayama City Hosp, Liver Dis Ctr, Okayama, Japan

[3] Kawasaki Med Sch, Gen Med Ctr, Dept Gen Internal Med 2, Okayama, Japan

[4] Osaka Metropolitan Univ, Grad Sch Med, Dept Hepatol, 1-4-3 Asahimachi,Abeno Ku, Osaka 5458585, Japan

[5] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[6] Yokohama City Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Yokohama, Kanagawa, Japan

[7] Gifu Municipal Hosp, Dept Gastroenterol & Hepatol, Gifu, Japan

[8] Saga Univ Hosp, Liver Ctr, Saga, Japan

[9] Saga Univ Hosp, Dept Lab Med, Saga, Japan

[10] Life Care Clin Hiroshima, Minami Ku, Hiroshima, Japan

[11] Kagawa Univ, Fac Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan

[12] Kochi Med Sch, Dept Gastroenterol & Hepatol, Nankoku, Kochi, Japan

[13] Kochi Prefectural Hata Kenmin Hosp, Dept Gastroenterol, Sukumo, Japan

[14] Hamamatsu Univ, Dept Internal Med 2, Hepatol Div, Sch Med, Hamamatsu, Shizuoka, Japan

[15] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka, Japan

[16] Asahikawa Med Univ, Dept Internal Med, Div Gastroenterol, Asahikawa, Hokkaido, Japan

[17] Urasoe Gen Hosp, Dept Gastroenterol, Urasoe, Japan

[18] Shimane Univ Hosp, Div Hepatol, Izumo, Shimane, Japan

[19] Suita Municipal Hosp, Dept Gastroenterol & Hepatol, Suita, Osaka, Japan

[20] Shimane Univ Hosp, Div Pathol, Izumo, Shimane, Japan

[21] Univ Ryukyus, Fac Med, Dept Internal Med 1, Nishihara, Okinawa, Japan

[22] Kagawa Univ, Fac Med, Div Innovat Med Hepatobiliary & Pancreatol, Miki, Kagawa, Japan

[23] Univ Ryukyus, Sch Med, Dept Clin Pharmacol & Therapeut, Nishihara, Okinawa, Japan

[24] Osaka Univ, Grad Sch Med, Dept Adv Metab Hepatol, Suita, Osaka, Japan

[25] Saga Univ Hosp, Liver Ctr, Saga, Japan

[26] Kyushu Univ, Dept Sci Pathol, Grad Sch Med Sci, Fukuoka, Japan

[27] Int Univ Healthcare & Welf, Grad Sch Healthcare Management, Minato Ku, Tokyo, Japan

[28] Gifu Kyoritsu Univ, Fac Nursing, Dept Nursing, Gifu, Japan

[29] Hepatol Ctr Saiseikai Suita Hosp, Suita, Osaka, Japan

来源：

HEPATOLOGY RESEARCH | 2024年 / 54卷 / 10期

关键词：

age; FIB-3; index; FIB-4; liver fibrosis; metabolic associated steatotic liver disease; TRANSIENT ELASTOGRAPHY; BIOPSY; FIB4;

D O I：

10.1111/hepr.14039

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aims: Because the accuracy of the Fibrosis-4 (FIB-4) index for predicting liver fibrosis changes with age, the need for different cut-offs in various age groups has frequently been discussed. We developed the age-independent score, the Fibrosis-3 (FIB-3) index, and have shown its usefulness in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to validate the diagnostic ability of the FIB-3 index to predict fibrosis progression using a large new patient cohort. Methods: The ability of the FIB-3 index to predict liver fibrosis was analyzed by comparing it with that of the FIB-4 index using data from 1398 patients with MASLD enrolled in the Asia-based clinical outcome NAFLD study. Results: The areas under the receiver operating characteristic curves for predicting fibrosis stage F3 or higher were not different between the FIB-3 and FIB-4 indices in the entire cohort. Using the single ideal cut-offs of the indices (3.41 for FIB-3 index and 2.01 for FIB-4 index), the predictive accuracy of the FIB-3 index was not significantly different from that of the FIB-4 index among patients aged <60 years; however, the accuracy of the FIB-3 index was significantly higher than that of the FIB-4 index in those aged >= 60 years (0.645 and 0.529, respectively; p < 0.0001). Conclusion: The high ability of the FIB-3 index with a single cut-off to predict liver fibrosis in patients with MASLD was confirmed. The FIB-3 index could serve as a useful tool for assessing liver fibrosis regardless of age.

引用

页码：912 / 920

页数：9

共 50 条

[21] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
Sohn, Won
Kwon, Heon-Ju
Chang, Yoosoo
Ryu, Seungho
Cho, Yong Kyun
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
[22] Artificial Intelligence and Image Analysis-Assisted Diagnosis for Fibrosis Stage of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Ultrasonography: A Pilot Study
Fujii, Itsuki
Matsumoto, Naoki
Ogawa, Masahiro
Konishi, Aya
Kaneko, Masahiro
Watanabe, Yukinobu
Masuzaki, Ryota
Kogure, Hirofumi
Koizumi, Norihiro
Sugitani, Masahiko
DIAGNOSTICS, 2024, 14 (22)
[23] Increased Prevalence of Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease Fibrosis in Type 2 Diabetics Despite Low-Risk Fibrosis-4 Index Scores
Woodard, Jordan S.
Abrams, Gary A.
JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 14 (01) : 40 - 47
[24] Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
Zong, Guannan
Mao, Wangjia
Wen, Ming
Cheng, Xiaoyun
Liu, Guanghui
ANNALS OF HEPATOLOGY, 2025, 30 (02)
[25] Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
Lee, Jun-Hyuk
Park, Jooyong
Ahn, Sang Bong
NUTRIENTS, 2024, 16 (01)
[26] FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease
Arvaniti, Pinelopi
Giannoulis, George
Lygoura, Vasiliki
Gatselis, Nikolaos K.
Gabeta, Stella
Rigopoulou, Eirini
Koukoulis, George K.
Zachou, Kalliopi
Dalekos, George N.
ANNALS OF GASTROENTEROLOGY, 2023, 36 (06): : 661 - 669
[27] Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
Zhang, Fan
Liu, Longgen
Li, Wenjian
NUTRITION JOURNAL, 2025, 24 (01)
[28] Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease
Hong, Shan
Hao, Yiwei
Sun, Lei
Li, Ping
Yang, Junru
Zhang, Fuyang
He, Lingling
Zhang, Jing
Wei, Hongshan
ANNALS OF HEPATOLOGY, 2025, 30 (02)
[29] The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults
Perumpail, Brandon J.
Manikat, Richie
Wijarnpreecha, Karn
Cholankeril, George
Ahmed, Aijaz
Kim, Donghee
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 79 (01) : 110 - 118
[30] Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
Boeckmans, Joost
Prochaska, Juergen H.
Gieswinkel, Alexander
Boehm, Michael
Wild, Philipp S.
Schattenberg, Joern M.
LANCET REGIONAL HEALTH-EUROPE, 2025, 48

← 1 2 3 4 5 →